MyFinsight
Home
Blog
About
Proceeds from exercise of
stock options
$1,280K
(207.69%↑ Y/Y)
Net cash provided by
(used in) financing...
$1,280K
(250.06%↑ Y/Y)
Effect of exchange rate
change on cash and cash...
$6K
(105.26%↑ Y/Y)
Net increase
(decrease) in cash and cash...
-$18,591K
(-41.17%↓ Y/Y)
Canceled cashflow
$1,286K
Stock-based compensation
$5,155K
(104.00%↑ Y/Y)
Non-cash interest
expense - royalty...
$2,308K
(-10.16%↓ Y/Y)
Accrued expenses and
other current...
$1,486K
(162.10%↑ Y/Y)
Accounts payable
$1,351K
(8.95%↑ Y/Y)
Change in fair value of
derivative liabilities -...
$114K
(-40.93%↓ Y/Y)
Non-cash lease operating
expense
$45K
Maturities of marketable
securities
$8,000K
Net cash used in
operating activities
-$12,845K
(-5.27%↓ Y/Y)
Net cash used in
investing activities
-$7,032K
Canceled cashflow
$10,459K
Canceled cashflow
$8,000K
Net loss
-$21,870K
(-23.87%↓ Y/Y)
Purchase of marketable
securities
$15,032K
Prepaid expenses and
other current assets
$1,065K
(210.94%↑ Y/Y)
Accretion on marketable
securities
$320K
Payments on operating
lease liabilities
-$49K
Back
Back
Cash Flow
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)
source: myfinsight.com